BCM
KURA icon

BlueCrest Capital Management’s Kura Oncology KURA Stock Holding History

BlueCrest Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,150
Closed -$89K – 1009
2017
Q1 		$89K Buy
+10,150
New +$74.4K ﹤0.01% 683

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's KURA Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Kura Oncology (KURA) in Q2 2017, closing a stake of 10,150 shares — an estimated $89K sold.

BlueCrest Capital Management first reported a position in KURA in Q1 2017 and held it in 1 quarter. The position peaked at $89K in Q1 2017. 44 funds tracked by Wall St. Rank hold KURA as of Q2 2017.

  • BlueCrest Capital Management reported no remaining Kura Oncology position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,150 Kura Oncology shares in Q2 2017, an estimated $89K.
  • BlueCrest Capital Management first reported a position in Kura Oncology in Q1 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Kura Oncology position peaked at $89K in Q1 2017.
  • 44 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.